Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Byetta Prescribers for Diabetes (US)

Articles with lock require a subscription to GLG News | Request a free trial
May 21, 2007
Bariatric surgery-- when all else fails in diabetic patients
Analysis of: Bariatric surgery - possible treatment for type 2 diabetes mellitus | www.news-medical.net
Author: GLG Expert Contributor
Bariatric surgery is a viable option for in properly selected, well-motivated, desperate patients with diabetes.
May 21, 2007
SoloStar may become the new star in insulin administration
Analysis of: FDA Approves Lantus SoloStar(R) A New Prefilled Disposable Insulin Pen For Use With LANTUS(R) In People With Type 1 And Type 2 Diabetes | www.medicalnewstoday.com
Author: GLG Expert Contributor
Pen delivery of insulin is the gold standard. SoloStar is as least as valuable a tool as the FlexPen.  The SoloStar will impact, mainly the short-acting analogue market, but should become the primary choice for Lantus administration.
April 29, 2007
Thiazolidinedione + Incretins=Weight Loss + Improved Glycemic Control
Analysis of: The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes | www.annals.org
Author: GLG Expert Contributor
Thiazolidinedione induced weight gain is mitigated with the addition of Exenatide, while improving glycemic control in Type 2 diabetes
April 29, 2007
Bariatric Surgery: Too much, Too early.
Analysis of: Bariatric surgery - possible treatment for type 2 diabetes mellitus | www.news-medical.net
Author: GLG Expert Contributor
Bariatric Surgery works to treat diabetes in the short run, but it is expensive and dangerous.
April 29, 2007
Lantus and Levemir, Separating the Wheat From the Chaff
Analysis of: New Data Confirm That Use Of Levemir® Can Limit Weight Gain | www.medicalnewstoday.com
Author: GLG Expert Contributor
Slight weight loss is demonstrated in a large observational study. This seems to support smaller studies. However, this is not a main advantage of Levemir.
April 29, 2007
Rebooting The Immune System-- Early Steps In A New Diabetes Treatment Direction
Analysis of: Rebooting the Immune System of Diabetics | www.technologyreview.com
Author: GLG Expert Contributor
Rebooting the immune system represents a new avenue to explore, but its very early in the process.
April 9, 2007
Exenatide and a TZD
Analysis of: The Effect of Adding Exenatide to a Thiazolidinedione in Suboptimally Controlled Type 2 Diabetes | www.annals.org
Author: GLG Expert Contributor
This article confirms what many of us had expected.  Enenatide works, as predicted, with a TZD with comparable reductions in A1c to other settings.  Many physicians had been previously using the combination "off label"  The study allowed the label to be modified to include the combination,...
March 30, 2007
New Pen, Old technology, More Money
Analysis of: Lilly Introduces World's First Digital Insulin Pen With Memory | www.medicalnewstoday.com
Author: GLG Expert Contributor
Old technology, limited usefulness More expensive than vials
Carlos DujovneMarch 22, 2007
Potential Benefit of Rimonabant on Fatty Liver.
Analysis of: Endocannabinoids as novel mediators of liver diseases. | www.ncbi.nlm.nih.gov
Author: Carlos Dujovne, Professor of Medicine and Director, OREGON HEALTH & SCIENCE UNIVERSITY - CC
1.)  Excessive accumulation of fat in the liver is a common occurrence in obesity and obesity comorbidities, such as diabetes and dyslipidemia.  2.) There has been no useful therapeutic intervention to remove fat from excessive deposits in the liver of these patients.  3.) Excessive...
Carlos DujovneMarch 22, 2007
Potential Additional Benefit from Rimonabant (Acomplia) Treatment
Analysis of: A therapeutic role for cannabinoid CB1 receptor antagonists in major depressive disorders. | www.ncbi.nlm.nih.gov
Author: Carlos Dujovne, Professor of Medicine and Director, OREGON HEALTH & SCIENCE UNIVERSITY - CC
1.) Depression is very common among the obese population. 2.) Suppressors of cannabinoid receptors are suspect of causing depression because of the euphoric effect of cannibinoids.3.) Rimonabant when tested in thousands of patients, in comparison to placebo caused a very small statistically insignificantly...

Previous Page : 1 2 3 4 5 6 7 8 9 Next71 to 80 of 90

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T09:45:16.773